首页|血清铁、CA19-9/GGT比值与肝细胞癌微血管侵犯、术后复发和预后的关系

血清铁、CA19-9/GGT比值与肝细胞癌微血管侵犯、术后复发和预后的关系

扫码查看
目的:分析血清铁、癌胚抗原19-9(CA19-9)/γ-谷氨酰转肽酶(GGT)比值与肝细胞癌微血管侵犯(MVI)、术后复发和预后的关系.方法:选择2020年3月至2023年3月我院收治的80例肝细胞癌患者(肝癌组)和53例健康志愿者(对照组),根据是否发生MVI将患者分为MVI组(46例)和非MVI组(34例).术前检测血清铁、CA19-9/GGT比值,术后定期随访,统计术后复发和总生存(OS)情况,根据复发情况分为复发组(26例)和非复发组(54例).受试者工作特征(ROC)曲线分析血清铁和CA19-9/GGT诊断术前MVI的价值.分析血清铁、CA19-9/GGT比值与肝细胞癌MVI、术后复发和预后的关系.结果:肝癌组血清铁、CA19-9/GGT比值均高于对照组(P<0.05),肝内转移、TNM分期Ⅲ期、低度分化肝细胞癌患者血清铁、CA19-9/GGT比值高于无肝内转移、TNM分期Ⅰ~Ⅱ期、高中分化患者(P<0.05).MVI组血清铁、CA19-9/GGT比值均高于非MVI组(P<0.05),复发组血清铁、CA19-9/GGT比值均高于非复发组(P<0.05).血清铁和CA19-9/GGT诊断术前MVI的截断值分别为56.98 µmol/L、2.53,曲线下面积为0.767、0.882,联合诊断为0.934,高于单独诊断(P<0.05).血清铁高水平、CA19-9/GGT高比值肝细胞癌患者OS生存率低于血清铁低水平、CA19-9/GGT低比值患者(P<0.05).TNM分期Ⅲ期、高血清铁水平、高CA19-9/GGT比值是肝细胞癌患者不良预后的危险因素(P<0.05).结论:肝细胞癌患者血清铁水平和CA19-9/GGT比值增高,与术前MVI、术后复发和预后不良有关.
Analysis of the relationship between serum iron,CA19-9/GGT ratio and microv-ascular invasion,postoperative recurrence and prognosis of hepatocellular carcinoma
Objective:To investigate the relationship between serum iron,carcinoembryonic antigen 19-9(CA19-9)/gamma-glutamyltranspeptidyase(GGT)ratio and microvascular invasion(MVI),postoperative recurrence and prognosis of hepatocellular carcinoma(HCC).Methods:A total of 80 patients with hepatocellular carcinoma(HCC group)and 53 healthy volunteers(control group)admitted to our hospital from March 2020 to March 2023 were selected,and the patients were divided into MVI group(46 cases)and non-MVI group(34 cases)according to whether MVI occurred.The serum iron and CA19-9/GGT ratio were detected before the operation,and postoperative recurrence and overall survival(OS)were analyzed by regular postoperative follow-up.The patients were divided into the recurrence group(26 cases)and non-recurrence group(54 cases)according to recurrence.The value of serum iron and CA19-9/GGT in preoperative diagnosis of MVI was analyzed by the receiver operating characteristic(ROC)curve.The relationship between serum iron,CA19-9/GGT ratio and MVI,postoperative recurrence,and prognosis of hepatocellular carcinoma was analyzed.Results:The serum iron and CA19-9/GGT ratios in HCC group were higher than those in control group(P<0.05).And the serum iron and CA19-9/GGT ratios in patients with intrahepatic metastasis,TNM stage Ⅲ and poorly differentiated hepatocellular carcinoma were higher than those without intrahepatic metastasis,TNM stage Ⅰ~Ⅱ and high school differentiation(P<0.05).The serum iron and CA19-9/GGT ratios in the MVI group were higher than those in non-MVI group(P<0.05),and serum iron and CA19-9/GGT ratios in the relapsed group were higher than those in non-relapsed group(P<0.05).The cut-off values of MVI before serum iron and CA19-9/GGT diagnosis were 56.98μmol/L and 2.53,respectively,the area under the curve was 0.767 and 0.882,and the combined diagnosis was 0.934,which were higher than those for single diagnosis(Z=3.498,2.303,P<0.05).The OS survival rate of patients with high serum iron levels and high CA19-9/GGT ratio was lower than that of patients with low serum iron levels and low CA19-9/GGT ratio(P<0.05).TNM stage Ⅲ,high serum iron level,and high CA19-9/GGT ratio were risk factors for poor prognosis in HCC patients(P<0.05).Conclusion:The increase of serum ferrate and CA19-9/GGT ratio in patients with hepatocellular carcinoma is related to preoperative MVI,postoperative recurrence,and poor prognosis.

hepatocellular carcinomamicrovascular invasionrecurrenceprognosisironcarcinoembryonic antigen 19-9/gamma-glutamyl transpeptidase ratio

陈红旭、庄宏宇、胡博、汪俊科

展开 >

重庆市渝北区人民医院(重庆,401120)

肝细胞癌 微血管侵犯 复发 预后 血清铁

2024

中西医结合肝病杂志
中国中西医结合学会,湖北中医学院

中西医结合肝病杂志

CSTPCD
影响因子:0.908
ISSN:1005-0264
年,卷(期):2024.34(7)
  • 2